on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Presents NFL-101 at Tobacco Congress
NFL Biosciences unveiled the mechanisms of action of NFL-101 at the annual meeting of the Société Francophone de Tabalogie. This innovative drug candidate is intended for smoking cessation. It is distinguished by a disruptive mechanism that could favorably impact smoking cessation.
The mechanism under study could offer smokers an effective alternative. NFL Biosciences demonstrates its continued commitment to the development of novel therapeutic solutions. The clinical efficacy of NFL-101 and its safety profile are currently being tested at the clinical scale.
The congress provided an ideal platform for the society to share its recent scientific advances. This presentation could mark a turning point in the treatment of tobacco use using innovative therapies.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news